Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint

Contemporary Clinical Trials

Volumn 32, Issue 1, 2011, Pages 99-107

  Kovalchik, Stephanie ^a   Mietlowski, William ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cytostatic agents; Growth modulation index; Paired failure times; Phase II design; Progression free survival

Indexed keywords

ARTICLE; CANCER SURVIVAL; GROWTH MODULATION INDEX; MEDICAL PRACTICE; METHODOLOGY; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; MODELS, STATISTICAL; NEOPLASMS; RESEARCH DESIGN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 78649907591     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2010.09.010     Document Type: Article

References (29)

1. Ratain M.J., Sargent D.J. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009, 45(2):275-280.
2. Suman V.J., Dueck A., Sargent D.J. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Invest 2008, 26(5):439-444.
3. Morabito A., Di M.M., De M.E., Normanno N., Perrone F. Methodology of clinical trials with new molecular-targeted agents: where do we stand?. Ann Oncol 2006, 17(vii):128-131.
4. Dhani N., Tu D., Sargent D.J., Seymour L., Moore M.J. Alternate endpoints for screening phase II studies. Clin Cancer Res 2009, 15(6):1873-1882.
5. Dagher R., Johnson J., Williams G., Keegan P., Pazdur R. Accelerated approval of oncology products. J Natl Cancer Inst 2004, 96:1500-1509.
6. Verweij J. Other endpoints in screening studies for soft tissue sarcomas. Oncologist 2008, 13:27-31.
7. Hoekstra R., Verweij J., Eskens F.A. Clinical trial design for target specific anticancer agents. Invest New Drugs 2003, 21:243-250.
8. Korn E.L., Liu P., Lee S.J., Chapman J.A.W., Niedzwiecki D., Suman V.J., et al. Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future Phase II trials. J Clin Oncol 2008, 26(4):527-534.
9. Bonetti A., Zaninelli M., Leone R., Franceschi T., Fraccon A., Pasini F., et al. Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma. Ann Oncol 2001, 12:187-191.
10. Bachet J., Mitry E., Liévre A., Lepére C., Vaillant J., Declety G., et al. Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. Gastroentérol Clin Biol 2009, 33:1036-1044.
11. Comella P., Casaretti R., Crucitta E., De Vita F., Palmeri S., Avallone A., et al. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer 2002, 86:1871-1875.
12. Gebbia V., Maiello E., Giuliani F., Borsellino N., Caruso M., Di M.G., et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the folfox4 regimen in clinical practice. Ann Oncol 2007, 18(vi):124-127.
13. Demetri G., Chawla S., von Mehren M., Ritch P., Baker L., Blay J., et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009, 27:4188-4196.
14. Mick R., Crowley J., Carroll R. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 2000, 21:343-359.
15. Owen W.J. A power analysis of tests for paired lifetime data. Lifetime Data Anal 2005, 11:233-243.
16. Newcombe R. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med 1998, 17:2635-2650.
17. Kaplan E., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
18. Tsiatis A.A. A large sample study of Cox's regression model. Ann Stat 1981, 9:93-108.
19. Kablfleisch J., Prentice R. The Statistical Analysis of Failure Time Data 1980, New York.
20. Borgan O., Liestol K. A note on confidence intervals and bands for the survival function based on transformations. Scand J Stat 1990, 17:35-41.
21. Lehmann E.L., D'Abrera H.J.M. Nonparametrics: Statistical Methods Based on Ranks 1975, Holden-Day, San Francisco.
22. Hudgens M., Satten G. Midrank unification of rank tests for exact, tied, and censored data. J Nonparametr Stat 2002, 14:569-581.
23. Hogg R.V., McKean J.W., Craig A.T. Introduction to Mathematical Statistics 2005, Pearson Prentice Hall, Upper Saddle River, NJ. 6th Edition.
24. McLachlan G., Krishnan T. The EM Algortihm and Extensions 1997, John Wiley & Sons, New York.
25. Le C.T. Fundamentals of Biostatistical Inference 1992, vol. 124. Dekker, New York.
26. Brumback L., Pepe M., Alonzo T. Using the ROC curve for gauging treatment effect in clinical trials. Stat Med 2006, 25:575-590.
27. Hougaard P. Analysis of Multivariate Survival Data 2000, Springer-Verlag, New York, NY.
28. Von Hoff D. There are no bad anticancer agents, only bad clinical trial designs: twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998, 4:1079-1086.
29. Rubinstein L.V., Korn E.L., Freidlin B., Hunsberger S., Ivy S.P., Smith M.A. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005, 23(28):7199-7206.